Traws Pharma, Inc. estimates Q3 2024 earnings per share of ($0.25) (NASDAQ:TRAW)

Traws Pharma, Inc. (NASDAQ:TRAW – Free Report) – Equities research analysts at Noble Financial issued their Q3 2024 earnings per share estimates for Traws Pharma in a report issued on Friday, August 16th. Noble Financial analyst R. Leboyer expects that the company will post earnings per share of ($0.25) for the quarter. Noble Financial also issued estimates for Traws Pharma Q4 2024 earnings at ($0.28) EPS, Q1 2025 earnings at ($0.31) EPS, Q2 2025 earnings at ($0.33) EPS, Q3 2025 at ($0.35) EPS at ($0.35) ) Revenue EPS and FY2025 at ($1.35) EPS.

Traws Pharma price performance

Shares of TRAW stock opened at $0.39 on Monday. The company has a market cap of $9.75 million, a P/E ratio of -0.44 and a beta of 1.37. The company has a 50-day moving average price of $0.42. Traws Pharma has a 1 year low of $0.33 and a 1 year high of $1.10.

Traws Pharma Company Profile

(Get a free report)

Traws Pharma, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery and development of novel products for the treatment of cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with the PD-1 inhibitor, which is in phase I/IIa study for patients with checkpoint inhibitor (CPI)-resistant K-Ras-mutated non-small cell lung cancer.

Featured stories

Get news and reviews for Traws Pharma Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Traws Pharma and related companies with MarketBeat.com’s FREE daily email newsletter.